target product profile

accelerated healing of surface wounds

  • dry eye (initial product)
  • skin wounds
  • mucous membranes
  • indications
    • signs/symptoms dry eye
    • epithelial eye damage (wounds), eye burns

qualities

  • allogeneic-serum-like, plasma-based
  • chitosan
  • multiuse, sterile, no preservatives
logo_barmedium

why plasma

  • resembles natural tears
  • growth factors
  • proteins
  • embraced by physicians
  • patient acceptance
  • extensive clinical data

why chitosan

  • safe medical grade available
  • accelerates wound healing
  • anti-microbial
  • non-immunogenic/ biodegradable
  • versatile excipient
solidgreen_bar

learn more about:

our products

Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. We believe this formulation will promote healing of epithelial (surface cell) disorders, such as dry eye disease, ophthalmic burns, and chronic wounds.

patients

Patients who experience conditions ranging from dry eye disease, to diabetic ulcers, and wounds or burns may benefit from our fusion of plasma and chitosan as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.

our platform

Our platform leverages plasma from donated human blood and a proprietary antimicrobial molecule (form of chitosan). The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, may provide relief and long-lasting therapeutic action.